Should You Buy Chemomab Therapeutics Ltd (CMMB) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
CMMB is not a good buy right now for a beginner, long-term investor with $50k–$100k. The stock remains in a broader bearish trend (long-term moving averages stacked bearishly), there are no fresh news catalysts, no supportive institutional/insider momentum, and the latest quarter shows widening losses with essentially no revenue. Given the user is impatient and not waiting for an optimal entry, the current setup does not offer an attractive long-term entry point—avoid/exit rather than buy.
Technical Analysis
**Trend/Setup**: Mixed-to-bearish. Although MACD is turning constructive, the longer-term trend is still down.
- **Moving Averages**: Bearish stack (SMA_200 > SMA_20 > SMA_5) indicates the prevailing trend is still negative.
- **MACD**: Histogram +0.0282 and expanding suggests improving short-term momentum, but it’s not enough to override the bearish MA structure.
- **RSI (6)**: 51.37 (neutral), no strong overbought/oversold edge.
- **Key Levels**: Support at **1.577 (S1)** then **1.502 (S2)**. Resistance at **1.697 (Pivot)** then **1.817 (R1)**. Price at **1.63** is below the pivot, implying overhead resistance.
- **Model-based near-term bias** (pattern analogs): Expected drift slightly negative (next month -2.63%), not supportive for an impatient entry.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): no signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.